Literature DB >> 21140224

An easy method to detect the kinetics of CD44 antibody and its receptors on B16 cells using atomic force microscopy.

Hua Jin1, Hongxia Zhao, Xianxian Chen, Lina Ma, Xun Huang, Hongyan Ye, Jiye Cai.   

Abstract

CD44 is the principle cell surface receptor for the extracellular matrix. The altered expression or dysfunction of CD44 proteins contributes to numerous pathological processes. Therefore, it is very necessary to detect the distribution and density of CD44 proteins on cell surface. In this paper, the unbinding force between the tip of an atomic force microscope modified with anti-human CD44 antibody (a kind of CD44 pathway ligation proteins, currently used to induce the apoptosis of some types of tumors) and B16 (human melanoma cell line) cells was measured. The results indicated that the distribution of CD44 was nonuniform and represented clusters on B16 cell surface. And, the data of kinetics of CD44 antibody-antigen binding experiments indicated that the CD44 signal pathway in B16 cells could be blocked by anti-CD44 monoclonal antibody. This methodology can be extended to the evaluation and screening of molecular targeted drugs for pharmacological use.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140224     DOI: 10.1007/s11033-010-0580-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  18 in total

1.  Chemomechanical mapping of ligand-receptor binding kinetics on cells.

Authors:  Sunyoung Lee; Jelena Mandic; Krystyn J Van Vliet
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

2.  Induction of apoptosis by anti-CD44 antibody in human chondrosarcoma cell line SW1353.

Authors:  Makoto Yoshida; Tadashi Yasuda; Teruko Hiramitsu; Hiromu Ito; Takashi Nakamura
Journal:  Biomed Res       Date:  2008-02       Impact factor: 1.203

3.  Atomic force microscopy investigation of phage infection of bacteria.

Authors:  Evgeniy V Dubrovin; Alexandr G Voloshin; Sergey V Kraevsky; Tatiana E Ignatyuk; Sergei S Abramchuk; Igor V Yaminsky; Sergei G Ignatov
Journal:  Langmuir       Date:  2008-10-14       Impact factor: 3.882

4.  Detection of erythrocytes influenced by aging and type 2 diabetes using atomic force microscope.

Authors:  Hua Jin; Xiaobo Xing; Hongxia Zhao; Yong Chen; Xun Huang; Shuyuan Ma; Hongyan Ye; Jiye Cai
Journal:  Biochem Biophys Res Commun       Date:  2009-12-27       Impact factor: 3.575

5.  CD44: target for antiangiogenesis therapy.

Authors:  Horace M DeLisser
Journal:  Blood       Date:  2009-12-10       Impact factor: 22.113

6.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells.

Authors:  Liqing Jin; Kristin J Hope; Qiongli Zhai; Florence Smadja-Joffe; John E Dick
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

Review 7.  CD44v6: a target for antibody-based cancer therapy.

Authors:  Karl-Heinz Heider; Hartmut Kuthan; Gerd Stehle; Gerd Munzert
Journal:  Cancer Immunol Immunother       Date:  2004-02-05       Impact factor: 6.968

8.  Anti-CD44 treatment abrogates tissue oedema and leukocyte infiltration in murine arthritis.

Authors:  K Mikecz; F R Brennan; J H Kim; T T Glant
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

9.  CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

Authors:  E Marangoni; N Lecomte; L Durand; G de Pinieux; D Decaudin; C Chomienne; F Smadja-Joffe; M-F Poupon
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

10.  Anti-CD44 induces apoptosis in T lymphoma via mitochondrial depolarization.

Authors:  Mohini Rajasagi; Anja von Au; Rahul Singh; Natalie Hartmann; Margot Zöller; Rachid Marhaba
Journal:  J Cell Mol Med       Date:  2009-09-18       Impact factor: 5.310

View more
  1 in total

1.  CD44 is associated with the aggressive phenotype of nasopharyngeal carcinoma through redox regulation.

Authors:  Chien-Hung Lin; Peir-Haur Hung; Yann-Jang Chen
Journal:  Int J Mol Sci       Date:  2013-06-26       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.